AminoActiv Treatment Regimen for Pain Management Promises Significantly Lower Consumer Costs Than Traditional Prescription NSAIDs

MADISON, Tenn., April 2, 2013 /PRNewswire/ -- In a one-year period, prescriptions for non-steroidal anti-inflammatory drugs (NSAIDs) cost the average consumer $2420. There are 33 million regular users of NSAIDs, and each user on average pays an additional $700 annually to treat side effects caused by their NSAIDs prescriptions. That's the takeaway from a study of current literature commissioned by Vireo Systems, Inc., the maker of AminoActiv®, a compelling new alternative to traditional NSAIDs.

The study compared AminoActiv with both prescription and generic NSAIDs and presented the following findings:

Annual Cost of Treatment Per Person:

• AminoActiv: $600
• Prescription NSAIDs: $2420

Side Effects Cost:

• AminoActiv: $0
• Prescription NSAIDs: $700

"The costs for just the side effects component of NSAID treatment exceed the total cost of AminoActiv treatment," stated Vireo Systems president Mark Faulkner. "To express it another way, if NSAID users obtained their prescriptions for free, they still would pay more to treat NSAID side effects."

AminoActiv offers comparable levels of pain and inflammation relief for a variety of chronic and acute conditions, along with promotion of more rapid healing, no known side effects, and no known toxicities or drug interactions.

Alternatives to NSAID treatment, including AminoActiv, are gaining traction for two major reasons. First, consumers are becoming more cognizant of the risks inherent in standard prescriptions like ibuprofen, naproxen (e.g. Naprosyn®), celecoxib (e.g. Celebrex®), and diclofenac. These risks include gastrointestinal issues, renal problems and cardiac complications. The risks are even greater for senior citizens. It is common for these side effects to result in hospitalization that costs between $15,000 and $20,000.

Second, there is a large group of consumers whose chronic diseases or organ sensitivities discourage or prevent them from using NSAIDs to alleviate pain.

"The surest method of lowering healthcare costs in America is preventing the need for treatment. Having access to a safe and effective OTC alternative such as AminoActiv empowers former NSAID users not only to lower their medical costs, but also to improve their quality of life," said Faulkner.

The Affordable Care Act of 2010 emphasizes prevention as essential to reeling in excessive healthcare costs. As such, the consumer's share of out-of-pocket costs for chronic care may noticeably increase. NSAID alternatives have the potential to reduce these costs dramatically.

"With almost 33 million people regularly using NSAIDs for pain and inflammation, the shift to safe, non-toxic alternatives will save our healthcare system billions annually," commented Faulkner.

AminoActiv is currently available as both a capsule and a topical cream. AminoActiv users report relief from a variety of pain conditions, including arthritis pain, joint & back pain, plantar fasciitis, and muscle strains. AminoActiv can be purchased at the online store or locally at select locations (http://aminoactiv.com/where-to-find-aminoactiv-locally/).

"As knowledge grows about the high cost of NSAIDs and their side effects, the demand for alternatives will only increase," concluded Faulkner. "AminoActiv's safety and performance record argues for its use as a first-line treatment for pain and inflammation."

To request more information about the research study, contact Mark Faulkner at 855-442-6466.

About Vireo Systems, Inc.

Taking inspiration from one of the Latin words for "health," Vireo Systems, Inc. is the manufacturer of a number of nutraceuticals and health promotion products including AminoActiv, the #1 alternative to ibuprofen and NSAIDs. Vireo was founded in 2002 as part of a project with several university-based researchers, and today, the company's products deliver safe, effective relief for inflammation and pain. Vireo meets industry-standard good manufacturing practices as expected by the FDA, and AminoActiv safety and toxicity data have been reviewed and accepted by the FDA.

Vireo is headquartered just outside Nashville, Tenn., with a secondary facility in Plattsmouth, Neb., where it manufactures its pain relief capsules and cream. Vireo is a two-time nominee for the NEXT Award, a prestigious honor celebrating successful businesses in the Middle Tennessee Region and part of an annual recognition program sponsored by the Nashville Area Chamber of Commerce and Entrepreneurial Center.

Naprosyn® is a registered trademark of Syntex Pharmaceuticals International.
Celebrex® is a registered trademark of Pfizer, Inc.

Contact:

Mark Faulkner
President, Vireo Systems, Inc.
855-442-6466
Email

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Vireo Systems, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED